Rybrevant® (amivantamab-vmjw) Referral Form

Preferred Clinic (select one): _____

VIVO infusion®

PATIENT INFORMATION

☐ New Referral ☐ Updated Referral ☐ Referral Renewal

DOB: Patient Name: Patient Phone:

Patient Address: Patient Email:

☐ NKDA Allergies: Weight (kg): Height:

ICD-10 Code (required): ICD-10 Description: Last Infusion Date: Last 4 Digits SSN:

PROVIDER INFORMATION

Referral Coordinator Name: Referral Coordinator Email:

Ordering Provider: Provider NPI:

Referring Practice Name: Phone: Fax:

Practice Address: City: State: Zip Code:

Physician Preferred Method of Contact: ☐ Email: ☐ Fax: ☐ Phone:

STANDING ORDERS

☑ Infusion to be administered per Vivo protocols.
☐ Infuse via Peripheral IV
☐ Infuse via Implanted Port
☐ Infuse via other vascular access device
_____

Laboratory Orders to be completed by referring office prior to infusion

Name and phone # of who to expect labs from: _____

☑ **Clinic Specimen Collection Authorization: If required labs are not received prior to appointment, infusion clinic staff are authorized to draw required labs under the referring provider's NPI and route results back to the referring office.**

☐ CBC w/ diff every _____

☐ CMP every _____

☐ OTHER _____

***Vivo Infusion will perform pregnancy screening prior to every infusion per Vivo policy*

PREMEDICATIONS **REQUIRED FOR INFUSION**

☐ acetaminophen (Tylenol) ☐ 500mg ☐ 650mg ☐ 1000mg PO
☐ dexamethasone 10mg IV
☐ dexamethasone 20mg IV
☐ diphenhydramine (Benadryl) ☐ 25mg ☐ 50mg ☐ PO ☐ IV
☐ methylprednisolone (Solu-Medrol) ☐ 40mg ☐ 125mg IV
☐ hydrocortisone (Solu-Cortef) ☐ 100mg IV
☐ Other: _____
Dose: _____ Route: _____

RYBREVANT ADMINISTRATION

☐ Single Agent

☐ With Lazertinib (Not provided by Vivo. Patient must self-administer prior to appointment)

☐ Patient less than 80 kg:
Week 1: Day 1 = 350 mg IV, Day 2 = 700 mg IV
Weeks 2-5: 1,050 mg IV weekly
Week 6: No dose
Week 7+: 1,050 mg every 2 weeks

☐ Patient greater than or equal to 80 kg:
Week 1: Day 1 = 350 mg IV, Day 2 = 1,050 mg IV
Weeks 2-5: 1,400 mg IV weekly
Week 6: No dose
Week 7+: 1,400 mg every 2 weeks

☐ Other: _____

REQUIRED DOCUMENTATION

☐ **Patient Demographics**
☐ **Insurance Card/Information**
☐ **Progress Notes Supporting DX**
☐ **Current Medication List and H&P**
☐ **EGFR gene mutation test results**
☐ **If taking Lazertinib, patient will receive anticoagulant prophylaxis to prevent venous thromboembolic (VTE) events for the first four months of treatment.**

Provider Name (Print) **Provider Signature** **Date**

Fax Referrals To: 855-314-0443 **Have a Question? Call (720) 902-4111**

Referral is valid for one year unless otherwise noted.

Revision Date 11/2026